MedTrace Logo

Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude

NCT00714740 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2014-05-20

No results posted yet for this study

Summary

The purpose of the study is to investigate the effect of acetazolamide as a treatment for sleep related breathing disturbances in patients with the obstructive sleep apnea syndrome living at low altitude during a sojourn at moderate altitude

Conditions

  • Obstructive Sleep Apnea Syndrome

Interventions

DRUG

acetazolamide

acetazolamide 2 times 250mg per day

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Konrad E Bloch, MD · Pulmonary Division, University Hospital Zurich, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00714740 on ClinicalTrials.gov